Abstract
Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Current HIV Research
Title: Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates.
Volume: 5 Issue: 2
Author(s): Radmila Metlas, Tanja Srdic and Veljko Veljkovic
Affiliation:
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Abstract: Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Export Options
About this article
Cite this article as:
Metlas Radmila, Srdic Tanja and Veljkovic Veljko, Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates., Current HIV Research 2007; 5 (2) . https://dx.doi.org/10.2174/157016207780077093
DOI https://dx.doi.org/10.2174/157016207780077093 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Human Recombinant Antibody to HSP90: A Natural Partner in Combination Therapy
Current Molecular Medicine Electronic-Topological Study of Structurally Diverse Cyclooxygenase-2 Inhibitors
Mini-Reviews in Medicinal Chemistry GDF11 Attenuated ANG II-Induced Hypertrophic Cardiomyopathy and Expression of ANP, BNP and Beta-MHC Through Down- Regulating CCL11 in Mice
Current Molecular Medicine Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes
Current Medicinal Chemistry Cognitive Impairment in the Septic Brain
Current Neurovascular Research Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Current Medicinal Chemistry CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
Current Gene Therapy Alcohol Consumption and Risk of Uterine Fibroids
Current Molecular Medicine Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs
Current Vascular Pharmacology The Role of Nuclear Factor-κB in Inflammatory Lung Disease
Inflammation & Allergy - Drug Targets (Discontinued) Classification of Small GTPases with Hybrid Protein Features and Advanced Machine Learning Techniques
Current Bioinformatics Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research The Endocannabinoid System May Modulate Sleep Disorders in Aging
Current Neuropharmacology Withdrawal Notice: Molecular Mechanism of TLR4 Mediated T Cell Immune Effect in Transfusion-induced Acute Lung Injury based on Slit2/Robo4 Signaling Pathway
Current Molecular Pharmacology Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design Microglia-Neuron Interaction in Inflammatory and Degenerative Diseases: Role of Cholinergic and Noradrenergic Systems
CNS & Neurological Disorders - Drug Targets Urocortin: Cardiovascular Actions and Therapeutic Implications
Letters in Drug Design & Discovery Exploring Optic Nerve Axon Regeneration
Current Neuropharmacology